Sign up
Pharma Capital

Ergomed to present at the International Society of Pharmacovigilance's Intelligent Automation

Can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?
Audiotorium
More than 30 speakers from the most influential companies in pharmacovigilance automation will present their state-of-the-art technologies

Ergomed Plc (LON:ERGO) said its pharmacovigilance subsidiary PrimeVigilance will be organising and presenting at the International Society of Pharmacovigilance's Intelligent Automation in Pharmacovigilance seminar.

The seminar will be held at Biogen's headquarters in Cambridge, Massachusetts, from 4-5 December 2017. It will seek to answer the question: Can automated processes powered by artificial intelligence provide effective solutions to the ever-increasing challenges in pharmacovigilance?

PrimeVigilance's chief executive officer, Jan Petracek, will be presenting the results from the company’s successful pilot project demonstrating how robotic process automation of selected pharmacovigilance systems can increase efficiency by up to 400 times, increasing speed, reducing cost and improving accuracy.

PrimeVigilance is working on the early deployment of robots in its operations.

"PrimeVigilance has consistently demonstrated growth, which is in no small part due to our market-leading adoption of new techniques and technologies and we are at the forefront of robotic automation, the next leap forward in technology for our industry,” Petracek said.

READ: Ergomed hopes to have PeproStat on the market by 2020 as it sails through Phase II trials

“We look forward to discussing these advances in pharmacovigilance automation and how they can increase efficiency and accuracy. Pharmacovigilance is an extremely fast-growing and highly regulated market and we are pleased to be able to share our views on meeting these increasingly complex regulatory requirements," he added.

John-H.jpg
Why Invest In Ergomed Plc? Read More Here

Register here to be notified of future ERGO Company articles
View full ERGO profile

Ergomed Plc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.